nach oben

Current Fungal Infection Reports

Erschienen in:

14.04.2016 | Current Management of Fungal Infections (RE Lewis, Section Editor)

Improved Radiographic Imaging of Invasive Fungal Disease: The Cornerstone to Antifungal Stewardship in the Hematology Units?

verfasst von: Marta Stanzani, Claudia Sassi, Giuseppe Battista, Michele Cavo, Russell E. Lewis

Erschienen in: Current Fungal Infection Reports | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Empirical or fever-driven antifungal treatment strategies are widely recognized to result in overtreatment of patients and excessive cost. As a result, diagnostic-driven approaches for managing invasive fungal diseases (IFDs) in hematology units have been proposed that rely on early non-specific radiologic findings frequent testing with non-culture-based biomarkers (e.g., galactomannan, PCR) as a trigger for antifungal treatment. However, the performance of these non-culture-based biomarker tests varies significantly from one center to the next, and their sensitivity is reduced by prior antifungal therapy. Moreover, many clinicians do not have sufficient confidence in their negative predictive value to withhold antifungal treatment. An alternative strategy is to use existing (computer tomography pulmonary angiography) and developing technologies (immune-positron emission tomography with specific antibodies) to improve the sensitivity and specificity radiological for IFD. Currently available data suggest that these newer techniques may have similar or better diagnostic performance as biomarker tests with high negative predictive values. In this monograph, we review challenges and recent progress in radiological imaging of IFD in hematology patients, and discuss its potential implications for antifungal stewardship.

Brown GD, Denning DW, Gow NAR, Levitz SM, Netea MG, White TC. Hidden killers: human fungal infections. Sci Transl Med. 2012;4:165rv13.CrossRefPubMed

Even C, Bastuji-Garin S, Hicheri Y, Pautas C, Botterel F, Maury S, et al. Impact of invasive fungal disease on the chemotherapy schedule and event-free survival in acute leukemia patients who survived fungal disease: a case-control study. Haematologica. 2011;96:337–41.CrossRefPubMed

Girmenia C, Micozzi A, Piciocchi A, Gentile G, Di Caprio L, Nasso D, et al. Invasive fungal diseases during first induction chemotherapy affect complete remission achievement and long-term survival of patients with acute myeloid leukemia. Leuk Res. 2014;38:469–74.CrossRefPubMed

Sharma S, Nadrous HF, Peters SG, Tefferi A, Litzow MR, Aubry M-C, et al. Pulmonary complications in adult blood and marrow transplant recipients: autopsy findings. Chest. 2005;128:1385–92.CrossRefPubMed

Lewis RE, Cahyame‐Zuniga L, Leventakos K. Epidemiology and sites of involvement of invasive fungal infections in patients with haematological malignancies: a 20‐year autopsy study. Mycoses. 2013;56:638–45.CrossRefPubMed

Pastores SM, Dulu AO, DeSouza SA. What has been learned from postmortem studies? Pulmonary involvement in patients with hematological malignancies. Springer Berlin Heidelberg; 2011. p. 243–54.

Shannon VR, Andersson BS, Lei X, Champlin RE, Kontoyiannis DP. Utility of early versus late fiberoptic bronchoscopy in the evaluation of new pulmonary infiltrates following hematopoietic stem cell transplantation. Bone Marrow Transplant. 2010;45:647–55.CrossRefPubMed

Marr KA, Laverdiere M, Gugel A, Leisenring W. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis. 2005;40:1762–9.CrossRefPubMed

9.•

Duarte RF, Sánchez-Ortega I, Cuesta I, Arnan M, Patiño B, de Sevilla Fernández A, et al. Serum galactomannan-based early detection of invasive aspergillosis in hematology patients receiving effective anti-mold prophylaxis. Clin Infect Dis. 2014;59:1696–702. Key study that demonstrates the limited diagnostic utility for serum galactomannan monitoring in patients receiving posaconazole prophylaxis.CrossRefPubMed

10.

Wang E, Farmakiotis D, Yang D, McCue DA, Kantarjian HM, Kontoyiannis DP, et al. The ever-evolving landscape of candidaemia in patients with acute leukaemia: non-susceptibility to caspofungin and multidrug resistance are associated with increased mortality. J Antimicrob Chemother Br Soc Antimicrob Chemo. 2015;70:2362–8.CrossRef

11.

Verweij PE, Chowdhary A, Melchers WJG, Meis JF. Azole resistance in Aspergillus fumigatus: can we retain the clinical use of mold-active antifungal azoles? Clin Infect Dis. 2016;62:362–8.CrossRefPubMed

12.

Pagano L, Caira M, Nosari A, Cattaneo C, Fanci R, Bonini A, et al. The use and efficacy of empirical versus pre-emptive therapy in the management of fungal infections: the HEMA e-Chart Project. Haematologica. 2011;96:1366–70.CrossRefPubMedPubMedCentral

13.

des Champs-Bro B, Leroy-Cotteau A, Mazingue F, Pasquier F, François N, Corm S, et al. Invasive fungal infections: epidemiology and analysis of antifungal prescriptions in onco-haematology. J Clin Pharm Ther. 2011;36:152–60.CrossRefPubMed

14.

Drgona L, Colita A, Klimko N, Rahav G, Ozcan MA, Donnelly JP. Triggers for driving treatment of at-risk patients with invasive fungal disease. J Antimicrob Chemother. 2013;68 Suppl 3:iii17–24.CrossRefPubMed

15.

Maertens J, Maertens V, Theunissen K, Meersseman W, Meersseman P, Meers S, et al. Bronchoalveolar lavage fluid galactomannan for the diagnosis of invasive pulmonary aspergillosis in patients with hematologic diseases. Clin Infect Dis. 2009;49:1688–93.CrossRefPubMed

16.

Girmenia C, Micozzi A, Gentile G, Santilli S, Arleo E, Cardarelli L, et al. Clinically driven diagnostic antifungal approach in neutropenic patients: a prospective feasibility study. J Clin Oncol. 2010;28:667–74.CrossRefPubMed

17.•

Morrissey CO, Chen SC-A, Sorrell TC, Milliken S, Bardy PG, Bradstock KF, et al. Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: a randomised controlled trial. Lancet Infect Dis. 2013;13:519–28. Key study demonstrating performance of a biomarker-guided strategy for IFD diagnosis.CrossRefPubMed

18.

Barnes R, Earnshaw S, Herbrecht R, Morrissey O, Slavin M, Bow E, et al. Economic comparison of an empirical versus diagnostic-driven strategy for treating invasive fungal disease in immunocompromised patients. Clin Ther. 2015;37:1317–28. e2.CrossRefPubMed

19.•

Ananda-Rajah MR, Slavin MA, Thursky KT. The case for antifungal stewardship. Curr Opin Infect Dis. 2012;25:107–15. Excellent review on the key challenges in implementing antifungal stewardship programs.CrossRefPubMed

20.

Maertens JA, Nucci M, Donnelly JP. The role of antifungal treatment in hematology. Haematologica. 2012;97:325–7.CrossRefPubMedPubMedCentral

21.

De Pauw B, Walsh TJ, Donnelly JP. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46:1813–21.CrossRefPubMedPubMedCentral

22.

Caillot D, Casasnovas O, Bernard A, Couaillier JF, Durand C, Cuisenier B, et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol. 1997;15:139–47.PubMed

23.

Brodoefel H, Vogel M, Hebart H, Einsele H, Vonthein R, Claussen C, et al. Long-term CT follow-up in 40 non-HIV immunocompromised patients with invasive pulmonary aspergillosis: kinetics of CT morphology and correlation with clinical findings and outcome. Am J Roentgenol. 2006;187:404–13.CrossRef

24.••

Nucci M, Nouér SA, Cappone D, Anaissi E. Early diagnosis of invasive pulmonary aspergillosis in hematologic patients: an opportunity to improve the outcome. Haematologica. 2013;98:1657–9. Thoughtful review of the pathogenesis of invasive mold disease and how CT imaging and biomarker performance varies depending on the host and timing of diagnostic studies.CrossRefPubMedPubMedCentral

25.

Greene RE, Schlamm HT, Oestmann J-W, Stark P, Durand C, Lortholary O, et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis. 2007;44:373–9.CrossRefPubMed

26.

Georgiadou SP, Sipsas NV, Marom EM, Kontoyiannis DP. The diagnostic value of halo and reversed halo signs for invasive mold infections in compromised hosts. Clin Infect Dis. 2011;52:1144–55.CrossRefPubMedPubMedCentral

27.••

Stanzani M, Sassi C, Lewis RE, Tolomelli G, Bazzocchi A, Cavo M, et al. High resolution computed tomography angiography improves the radiographic diagnosis of invasive mold disease in patients with hematological malignancies. Clin Infect Dis. 2015;60:1603–10. First study to describe the diagnostic performance of CTPA performance versus other angioinvasive CT signs for invasive mold disease.CrossRefPubMed

28.

Wahba H, Truong MT, Lei X, Kontoyiannis DP, Marom EM. Reversed halo sign in invasive pulmonary fungal infections. Clin Infect Dis. 2008;46:1733–7.CrossRefPubMed

29.

Jung J, Kim MY, Lee HJ, Park YS, Lee S-O, Choi S-H, et al. Comparison of computed tomographic findings in pulmonary mucormycosis and invasive pulmonary aspergillosis. Clin Microbiol Infect. 2015;21:684. e11–8.CrossRefPubMed

30.

Legouge C, Caillot D, Chrétien ML, Lafon I, Ferrant E, Audia S, et al. The reversed halo sign: pathognomonic pattern of pulmonary mucormycosis in leukemic patients with neutropenia? Clin Infect Dis. 2014;58:672–8.CrossRefPubMed

31.

Chamilos G, Marom EM, Lewis RE, Lionakis MS, Kontoyiannis DP. Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin Infect Dis. 2005;41:60–6.CrossRefPubMed

32.

Greene R. The radiological spectrum of pulmonary aspergillosis. Med Mycol. 2005;43 Suppl 1:S147–54.CrossRefPubMed

33.

Horger M, Einsele H, Schumacher U, Wehrmann M, Hebart H, Lengerke C, et al. Invasive pulmonary aspergillosis: frequency and meaning of the “hypodense sign” on unenhanced CT. Br J Radiol. 2005;78:697–703.CrossRefPubMed

34.

Nucci M, Nouér SA, Grazziutti M, Kumar NS, Barlogie B, Anaissie E. Probable invasive aspergillosis without prespecified radiologic findings: proposal for inclusion of a new category of aspergillosis and implications for studying novel therapies. Clin Infect Dis. 2010;51:1273–80.CrossRefPubMed

35.

Franquet T, Müller NL, Oikonomou A, Flint JD. Aspergillus infection of the airways: computed tomography and pathologic findings. J Comput Assist Tomogr. 2004;28:10–6. journals.lww.com.CrossRefPubMed

36.

Franquet T, Müller NL, Giménez A, Guembe P, de La Torre J, Bagué S. Spectrum of pulmonary aspergillosis: histologic, clinical, and radiologic findings. Radiographics. 2001;21:825–37. pubs.rsna.org.CrossRefPubMed

37.

Orr DP, Myerowitz RL, Dubois PJ. Patho-radiologic correlation of invasive pulmonary aspergillosis in the compromised host. Cancer. 1978;41:2028–39. Wiley Online Library.CrossRefPubMed

38.

Kyo K, Ochi T, Okatani T, Itagaki M, Imanaka R, Katayama Y, Kyo T. Is the halo sign the earliest sign of pulmonary invasive aspergillosis? In: American Society for Microbiology, editor. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology; p. M – 159.

39.

Bergeron A, Porcher R, Sulahian A, De Bazelaire C, Chagnon K, Raffoux E, et al. The strategy for the diagnosis of invasive pulmonary aspergillosis should depend on both the underlying condition and the leukocyte count of patients with hematologic malignancies. Blood. 2012;119:1831–7. Am Soc Hematology.CrossRefPubMed

40.

Hope WW, Petraitis V, Petraitiene R, Aghamolla T, Bacher J, Walsh TJ. The Initial 96 hours of invasive pulmonary aspergillosis: histopathology, comparative kinetics of galactomannan and (1→3)-β-d-glucan, and consequences of delayed antifungal therapy. Antimicrob Agents Chemother. 2010;54:4879–86.CrossRefPubMedPubMedCentral

41.

Lengerova M, Kocmanova I, Racil Z, Hrncirova K, Pospisilova S, Mayer J, et al. Detection and measurement of fungal burden in a guinea pig model of invasive pulmonary aspergillosis by novel quantitative nested real-time PCR compared with galactomannan and (1, 3)-beta-D-glucan detection. J Clin Microbiol. 2012;50:602–8.CrossRefPubMedPubMedCentral

42.••

Sonnet S, Buitrago-Téllez CH, Tamm M, Christen S, Steinbrich W. Direct detection of angioinvasive pulmonary aspergillosis in immunosuppressed patients: preliminary results with high-resolution 16-MDCT angiography. AJR Am J Roentgenol. 2005;184:746–51. First study to describe a CTPA performance for diagnosis of angioinvasive mold infection.CrossRefPubMed

43.•

Stanzani M, Battista G, Sassi C, Lewis RE, Tolomelli G, Clissa C, et al. Computed tomographic pulmonary angiography for diagnosis of invasive mold diseases in patients with hematological malignancies. Clin Infect Dis. 2012;54:610–6. Key follow-up study that confirmed the potential utility of CTPA for diagnosis of invasive mold disease.CrossRefPubMed

44.

Herbrecht R, Roedlich M-N. Earlier diagnosis of angioinvasive pulmonary mold disease: is computed tomography pulmonary angiography a new step? Clin Infect Dis. 2012;54:617–20.CrossRefPubMed

45.

Glaudemans AWJM, de Vries EFJ, Galli F, Dierckx RAJO, Slart RHJA, Signore A. The use of (18)F-FDG-PET/CT for diagnosis and treatment monitoring of inflammatory and infectious diseases. Clin Dev Immunol. 2013;2013:623036.CrossRefPubMedPubMedCentral

46.•

Chamilos G, Macapinlac HA, Kontoyiannis DP. The use of 18F-fluorodeoxyglucose positron emission tomography for the diagnosis and management of invasive mould infections. Med Mycol. 2008;46:23–9. Descriptive series of FDG-PET performance in patients with hematological malignancies.CrossRefPubMed

47.

Kumar R, Basu S, Torigian D, Anand V, Zhuang H, Alavi A. Role of modern imaging techniques for diagnosis of infection in the era of 18F-fluorodeoxyglucose positron emission tomography. Clin Microbiol Rev. 2008;21:209–24.CrossRefPubMedPubMedCentral

48.

Kim JY, Yoo J-W, Oh M, Park SH, Shim TS, Choi YY, et al. (18)F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography findings are different between invasive and noninvasive pulmonary aspergillosis. J Comput Assist Tomogr. 2013;37:596–601.CrossRefPubMed

49.

Marom EM, Kontoyiannis DP. Imaging studies for diagnosing invasive fungal pneumonia in immunocompromised patients. Curr Opin Infect Dis. 2011;24:309–14.CrossRefPubMed

50.

Hot A, Maunoury C, Poiree S, Lanternier F, Viard JP, Loulergue P, et al. Diagnostic contribution of positron emission tomography with [18F]fluorodeoxyglucose for invasive fungal infections. Clin Microbiol Infect. 2011;17:409–17.CrossRefPubMed

51.

Xu B, Shi P, Wu H, Guo X, Wang Q, Zhou S. Utility of FDG PET/CT in guiding antifungal therapy in acute leukemia patients with chronic disseminated candidiasis. Clin Nucl Med. 2010;35:567–70.CrossRefPubMed

52.

Mahfouz T, Miceli MH, Saghafifar F, Stroud S, Jones-Jackson L, Walker R, et al. 18F-fluorodeoxyglucose positron emission tomography contributes to the diagnosis and management of infections in patients with multiple myeloma: a study of 165 infectious episodes. J Clin Oncol. 2005;23:7857–63.CrossRefPubMed

53.

Petrik M, Franssen GM, Haas H, Laverman P, Hörtnagl C, Schrettl M, et al. Preclinical evaluation of two 68Ga-siderophores as potential radiopharmaceuticals for Aspergillus fumigatus infection imaging. Eur J Nucl Med Mol Imaging. 2012;39:1175–83.CrossRefPubMedPubMedCentral

54.

Yang Z, Kontoyiannis DP, Wen X, Xiong C, Zhang R, Albert ND, et al. Gamma scintigraphy imaging of murine invasive pulmonary aspergillosis with a 111 In-labeled cyclic peptide. Nucl Med Biol. 2009;36:259–66. Elsevier.CrossRefPubMed

55.•

Rolle A-M, Hasenberg M, Thornton CR, Solouk-Saran D, Männ L, Weski J, et al. ImmunoPET/MR imaging allows specific detection of Aspergillus fumigatus lung infection in vivo. Proc Natl Acad Sci U S A. 2016;113:E1026–33. First study to demonstrate improved specificity of PET imaging for invasive aspergillosis using a monoclonal antibody directed against cell wall mannoprotein.CrossRefPubMedPubMedCentral

56.

Cooke FJ, Holmes AH. The missing care bundle: antibiotic prescribing in hospitals. Int J Antimicrob Agents. 2007;30:25–9. Elsevier.CrossRefPubMed

57.•

Stanzani M, Lewis RE, Fiacchini M, Ricci P, Tumietto F, Viale P, et al. A risk prediction score for invasive mold disease in patients with hematological malignancies. PLoS One. 2013;8:e75531. A study that describes a validated clinical risk score for invasive mold disease in patients with hematological malignancies.CrossRefPubMedPubMedCentral

58.

Maertens J, Marchetti O, Herbrecht R, Cornely OA, Flückiger U, Frêre P, et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3–2009 update. Bone Marrow Transplant. 2011;46:709–18. Nature Publishing Group.CrossRefPubMed

Titel: Improved Radiographic Imaging of Invasive Fungal Disease: The Cornerstone to Antifungal Stewardship in the Hematology Units?
verfasst von: Marta Stanzani
Claudia Sassi
Giuseppe Battista
Michele Cavo
Russell E. Lewis
Publikationsdatum: 14.04.2016
Verlag: Springer US
Erschienen in: Current Fungal Infection Reports / Ausgabe 2/2016
Print ISSN: 1936-3761
Elektronische ISSN: 1936-377X
DOI: https://doi.org/10.1007/s12281-016-0258-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Improved Radiographic Imaging of Invasive Fungal Disease: The Cornerstone to Antifungal Stewardship in the Hematology Units?

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2016

Next-Generation Sequencing in the Mycology Lab

Therapeutic Drug Monitoring of Posaconazole: an Update

Impact of New Diagnostic Approaches for Invasive Candidiasis on Antifungal Stewardship

Evolution of Cryptococcal Antigen Testing: What Is New?

Point of Care Testing for the Diagnosis of Fungal Infections: Are We There Yet?

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin